-
1 Comment
Zoono Group Limited is currently in a long term downtrend where the price is trading 36.6% below its 200 day moving average.
From a valuation standpoint, the stock is 54.3% cheaper than other stocks from the Consumer Defensive sector with a price to sales ratio of 3.1.
Zoono Group Limited's total revenue rose by 741.1% to $14M since the same quarter in the previous year.
Its net income has increased by 361.7% to $2M since the same quarter in the previous year.
Finally, its free cash flow grew by 938.0% to $2M since the same quarter in the previous year.
Based on the above factors, Zoono Group Limited gets an overall score of 4/5.
Exchange | AU |
---|---|
CurrencyCode | AUD |
ISIN | AU000000ZNO4 |
Sector | Consumer Defensive |
Industry | Household & Personal Products |
Target Price | None |
---|---|
Beta | 1.15 |
PE Ratio | None |
Market Cap | 12M |
Dividend Yield | None |
Zoono Group Limited, together with its subsidiaries, engages in the research, development, and sale of a range of antimicrobial products in New Zealand, Australasia, Asia, the United States, India, the United Kingdom, and Europe. Its products include hand and surface sanitisers, textile applicator, and mould remediation products. The company serves facilities management, transportation, education, hospitality, and healthcare sectors. Zoono Group Limited was founded in 2007 and is headquartered in Auckland, New Zealand.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ZNO.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025